ArmaGen Technologies, a US-based life sciences company known as Neurogene Technologies until 2004, has raised $17m in its series A round from four corporations.
Boehringer Ingelheim Venture Fund, the corporate venturing unit of the eponymous Germany-based healthcare company, led the A round syndicate, which also included drug peers Shire and Takeda’s venturing units, and Japan-based financial conglomerate Mitsui’s Global Investment division.
William Pardridge, founder and chief scientific officer of ArmaGen and professor of medicine and director of the Blood Brain…
